[A complete response following treatment with Paclitaxel and bevacizumab for metastatic breast cancer].

Abstract

A 60-year-old woman with left breast cancer underwent partial mastectomy and sentinel lymph node biopsy. Pathological examination revealed an invasive ductal carcinoma that was ER (+), PgR (-), HER2 (-), and node positive (1/1). She received adjuvant chemotherapy with doxorubicin and cyclophosphamide (AC), followed by weekly paclitaxel (PTX). After receiving radiation therapy, she was administered an aromatase inhibitor for 5 years. Six months after completion of therapy, she found a hard lymph node in the left infraclavicular area. Fine needle aspiration cytology of the lymph node indicated metastatic breast cancer. Fulvestrant was administered but disease progression was observed after 3 months. Systemic chemotherapy with PTX and bevacizumab (Bev) was begun. After 3 cycles of chemotherapy, computed tomography (CT) scan revealed a complete response (CR). After 6 cycles of chemotherapy, the CR has been maintained.

• Authors: Yu Tsubota, Noriko Sueoka, Daigo Yamamoto
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 41 Issue 12 Pg. 1954-6 (Nov 2014) ISSN: 0385-0684 [Print] Japan
• PMID: 25731387 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Paclitaxel

Topics

• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bevacizumab
• Breast Neoplasms (drug therapy, pathology)
• Carcinoma, Ductal, Breast (drug therapy, secondary)
• Combined Modality Therapy
• Female
• Humans
• Lymphatic Metastasis
• Middle Aged
• Paclitaxel (administration & dosage)
• Remission Induction